Key takeaways
- For one 70-year-old patient, the clock may never line up, and her doctor's next suggestion carries hidden costs.
- The test is Galleri, from Grail (NASDAQ:GRAL | GRAL Price Prediction), and its list price is $949.
- Grail lists the test at $949, but says many doctors and health systems offer it for $799 or less.
Congress finally cleared a path for Medicare to cover a multi-cancer blood test, but a quirk in the fine print moves the goalposts every year. For one 70-year-old patient, the clock may never line up, and her doctor's next suggestion carries hidden costs.
See the latest quote, chart and news for GRAL.
